Maynard Um
-
-
-
-
-
-
-
Truist Securities Assumes Arcus Biosciences (RCUS) at Buy
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Raised to $49 at Leerink Partners
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Lowered to $44 at Citi
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Raised to $39 at Truist Securities
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Misses Q1 EPS by 12c
-
-
-
-
-
-
-
Barclays shares outlook for Biotech in 2025, names preferred stocks
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
-
448,077 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

